MSD getting closer to USD 40bn acquisition of Seagen, media reports
US-based pharmaceutical giant MSD is in advanced negotiations concerning the acquisition of Seagen, a biotech firm focusing on oncology, for around USD 40bn, the Wall Street Journal reports after speaking to people close to the matter.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Evaxion Biotech's lung cancer candidate ready for clinic
For subscribers
MSD eyeing Seagen acquisition, media reports
For subscribers